Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-α and Chemokine Production by Human Lung Parenchyma

BACKGROUND: Roflumilast is the first phosphodiesterase-4 (PDE4) inhibitor to have been approved for the treatment of COPD. The anti-inflammatory profile of PDE4 inhibitors has not yet been explored in human lung tissues. We investigated the effects of roflumilast and its active metabolite roflumilas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Buenestado, Amparo, Chaumais, Marie-Camille, Grassin-Delyle, Stanislas, Risse, Paul-André, Naline, Emmanuel, Longchampt, Elisabeth, Tenor, Hermann, Devillier, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3774805/
https://ncbi.nlm.nih.gov/pubmed/24066150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0074640
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados